Pandorum Technologies is moving its exosome platform closer to the clinic.
The regenerative medicine company has announced a strategic manufacturing collaboration with Hyderabad-based Nucelion Therapeutics, a specialized CRDMO, to expand production of its exosome-based therapies across the Asia-Pacific (APAC) region.
This is a scale and readiness move. Not a science headline.
Pandorum’s programs are advancing toward clinical trials. Manufacturing, consistency, and regional regulatory readiness now matter as much as biology.
By partnering with Nucelion, Pandorum gains:
It also reinforces India’s role in next-generation biologics manufacturing.
Pandorum is developing a programmable exosome platform designed to:
The company’s strategy is clear: Build once. Scale globally. Partner early.
“As our programs advance toward clinical and commercial milestones, establishing robust, regionally aligned manufacturing infrastructure is a strategic priority,”
Nucelion Therapeutics brings:
The immediate focus is Kuragenx, Pandorum’s exosome-based therapy for ocular diseases.
“We look forward to enabling the scalable production of Pandorum’s designer exosome-based assets for patients across the APAC region,”
Current programs target high unmet need indications, including:
These are areas where conventional therapies fall short.
Pandorum’s ambitions extend well beyond ophthalmology. Future programs aim to address:
The underlying bet: exosomes as programmable regenerative tools, not just delivery vehicles.
The collaboration also drew support from BIRAC, under India’s Department of Biotechnology.
“This partnership sends a strong signal toward the readiness of Innovate and Make in India for addressing unmet global clinical needs,”
It reflects a broader trend: India moving from volume manufacturing to complex, frontier biologics.
This is not a flashy clinical update. It is more important. Pandorum is quietly doing the hard work:
For regenerative medicine companies, this is how clinical ambition becomes commercial reality.